Affimed Announces First Patient Successfully Dosed in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced EGFR-Expressing Solid Tumors Including Colon, Lung and Other Cancers
April 16, 2020
April 16, 2020
April 2, 2020
April 2, 2020
March 26, 2020
March 17, 2020
February 19, 2020
February 3, 2020
January 10, 2020
December 18, 2019
November 19, 2019